← All trials
NCT03249181
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2018
- Primary completion
- Sep 30, 2020
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LiverpoolLead sponsor
- Radboud UniversityCollaborator
- University of LiverpoolCollaborator
- University of LiverpoolReponsible party - principal investigator
- University of LiverpoolStudy chair
- University of Cape TownCollaborator
- Infectious Disease Institute, Kampala, UgandaCollaborator
- UNITAIDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.